vaxxas crop.png
Company Profile:

Vaxxas

Vaxxas is developing an advanced platform for needle-free vaccine delivery. The Nanopatch™ comprises an ultra-high-density array of very short projections—invisible to the naked human eye–coated with vaccine. Applying the Nanopatch™ to skin is pain free, rapidly delivering vaccine directly to the abundant populations of immune cells immediately below the skin’s surface. Preclinical and clinical studies show this approach can be more efficient at producing immune response than a syringe. And, vaccine coated on the Nanopatch™ can be stable for more than a year at room temperature. This not only eliminates the cost and logistics burden needed for refrigeration during transportation and storage, but can also extend the reach of vaccines to remote regions and the developing world to significantly improve healthcare and disease prevention.

Q&A with Vaxxas

Q: What is the story behind the central idea that inspired the creation of your organization/company?

A: Extending the reach and performance of vaccines. Evolution gifted humans with thousands of times greater density of immune cells in the skin than systemically for a good reason; survival. Targeting vaccine to these dense populations of immune cells in the skin can improve performance of vaccines and help to fight debilitating and deadly diseases. And eliminating the need for refrigeration can extend the reach life-saving vaccines to difficult-to-access regions.

Q: What's the most inventive, innovative, or disruptive aspect of your initiative?

A: The Nanopatch can eliminate the need for refrigeration and is designed for ease of use by low-skilled health workers. This powerful combination can extend the reach of vaccination in ways not possible today, improving health outcomes and positively impacting millions of lives.  

Q: If you had a theme song, what would it be and why?

A: As an Australian company, perhaps it is "From Little Things, Big Things Grow" by Paul Kelly. The specific content of the song is not in our domain; but it's a story of tenacity bringing change, and that is definitely us!

Q: What single word or phrase best describes the culture of your startup and why?

A: “Every second counts; in lives." Every day thousands of people die needlessly from diseases that can be prevented through vaccination. Our technology can extend the reach of vaccines and help fundamental move the balance of that equation. Bringing biotechnology products to market is lengthy and complex; work smart, stay focused, and remember that every second counts; in lives. 


Leadership:
David Hoey
CEO
2018 David's Hive Talk View Website
David-Hoey-headshot-crop.jpg
Entrepreneur Profile:

David Hoey
CEO
David Hoey, CEO, has more than 25 years of executive-level experience in business development, licensing, strategic planning, and financing for technology companies. His experience spans preclinical and clinical development of therapeutics and vaccines, and molecular diagnostic assays and platforms. Mr. Hoey has completed over $425 million in corporate partnering transactions and equity financings in the United States, Europe, and Japan and has secured extensive contracts for government sponsored research. Mr. Hoey is a board member of publicly listed Universal Biosensors Pty. Ltd.
Company: Back
vaxxas-full.jpg 2018